2016第八届国际抗体大会
时间：2016年4月25-28日
地点：中国 大连
主题：加速下一代抗体的研发
会议网站：http://www.bitcongress.com/ica2016/default.asp

       国际抗体大会已经成功举办过七届，已成为全球抗体研究领域最专业的会议之一。大会致力于为全球的科学工作者、研究机构和相关企业搭建一个自由交流的平台，加强政府组织、大学、研究机构和企业之间的沟通与协作，进一步推进中国和全世界在抗体研究和治疗领域的新进展。
       本届大会交流内容包括抗体研究新技术新趋势，抗体药物研发及治疗，抗体医疗诊断，抗体工程及生产、商务合作等20多个专业性论坛，旨在传递抗体研究领域各个方面的最新资讯，展示突破性研究成果。大会组委会将邀请3位诺贝尔奖大师出席开幕式，并做主题报告。还将邀请国际著名专家学者、抗体研发国际重点实验室、大学、研究所的主要负责人、抗体生产和销售企业的高管做专题报告。

主题演讲人
Dr. Patrick Liu, Vice President, Teva Pharmaceuticals Ltd., USA
Dr. Jose de Chastonay, Chief Marketing Officer, Bachem Holding AG, Switzerland
Dr. Vadim T. Ivanov, Director and Professor, Russian Academy of Sciences, Russia
Dr. Kelly T. McKee, Vice President, Quintiles Inc., USA
Dr. Zhenping Zhu, Executive Vice President, Biologics President & CEO, Kadmon China, USA

英文分组论坛（演讲语言为英文）

Track 1 Global Antibody Market Trend, Business and Partnering
Track 1-1 Promising Future and Challenge, Business and Cooperation in World Antibody Market
Track 1-2 Industry Aspects, Policy, Regulation, IP Issues, Business and Trends in Antibody Market
Track 1-3 IP Issues

Track 2 New Technologies and Trends in Antibody Research
Track 2-1: Novel Research in Immune System, Immunology and Immunogenicity of Antibodies
Track 2-2: Immunoglobulin Diversity, Antibody Characterization Technologies and Structure Biology
Track 2-3: Novel Antibody Library Technologies and Microarray Technologies, Nanotechnology, Biochips, Phage Display Technologies for Antibody Research
Track 2-4: Enabled High Throughput/Content Technologies for Antibody Research - From Antibody Screening, Selection to Optimization Technologies
Track 2-5: Antibody Humanization Technologies
Track 2-6: Exploiting the Immune System and Immunotherapeutic Strategies – from Vaccines to Cell-based and Protein Immunotherapy
Track 2-7: Glycoengineered Antibodies, Agonist and Super-agonist Antibodies
Track 2-8: Monovalent, Multivalent Antibodies, Fragments, Single-domain Antibody, and scFv

Track 3 Advances in Antibody Drug and Therapy
Track 3-1: Challenges and New Opportunities with Antibody and Protein Drugs
Track 3-2: Innovative Antibody drugs in Clinical Trail and Development
Track 3-3: Novel Antibody and Biologic Drug Targets
Track 3-4: Antibody-drug Conjugate (ADC) Discovery and Development
Track 3-5: Bispecific and Multispecific antibody discovery and development
Track 3-6: Next Generation of Cancer Immune therapy and Anti-Cancer Antibody
Track 3-7: Novel Therapeutic Antibodies for Infectious and Inflammatory Diseases
Track 3-8: Novel Therapeutic Antibodies for Allergy, Asthma and Autoimmune Diseases
Track 3-9: Antibodies for Pediatrics Diseases
Track 3-10: Therapeutic Antibodies for Neurological Disease and other Neglected Diseases

Track 4 Antibody Applications in Medical Diagnosis and other Non-Medical Field
Track 4-1: Novel Antibodies in Medical Treatment and Diagnosis
Track 4-2: Biomarker Development - Correlating with Antibody Therapy
Track 4-3: Antibodies for Immunohistochemistry and Immunofluorescence
Track 4-4: Antibody for Western Blot Analyses, ELISA and ELISPOT Techniques
Track 4-5: Antibody Research in Agriculture, Aquaculture, Veterinary and Food Sciences
Track 4-6: The “standardisation” of Methods Using Antibodies for the Detection of Diseases and other Issues

Track 5 Antibody Design, Engineering and Production
Track 5-1: Analytical Strategies for Early Phase Protein Engineering and New Antibody Formats
Track 5-2: Advances in Antibody Engineering and Design Strategies
Track 5-3: Cell Line and Model Organisms Development for Antibodies
Track 5-4: Novel Upstream Bioprocess Technologies in Antibody Production
Track 5-5: Optimised Platform for Downstream Processing of Antibodies
Track 5-6: Improved Purification and Modification Methods for Antibody Fragments
Track 5-7: Novel Expressing Platform for Antibody Production
Track 5-8: Biosimilars and Biobetters - Methods and Protocols

如果您有演讲或参会的意向，请先与会务组联系。

联系方式
联系人：张女士
电话：0411-84799609-842
邮箱：dannie@bit-ica.com
地址：大连市高新园区汇贤园 1 号 11 层 
邮编：116025